Navigation Links
Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well,Tolerated in Phase 3 Study

Patients Using ROX-888 Required Significantly Less Morphine After Major Abdominal Surgery Company On Track To File NDA In 2008

MENLO PARK, CA (June 6, 2007) – ROXRO PHARMA Inc. said today that ROX-888, its novel intranasal analgesic, rapidly and effectively eased pain and was well tolerated by patients who had undergone major abdominal surgery in a Phase 3 clinical study.

"This completes our second and final Phase 3 clinical study," said ROXRO PHARMA’s Chief Scientific Officer Roger Whiting. The company intends to include fully analyzed data in its New Drug Application for submission to the U.S. Food and Drug Administration. "We are very pleased with the solid results of this Phase 3 study and are on track to file our NDA in the first half of 2008," Whiting said.

In the Phase 3 study, patients who received ROX-888 reported greater improvement in pain relief and required 22 percent less morphine in the first 24 hours following surgery compared to patients who had access to morphine alone. ROX-888 is an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory medicine most often administered as an intramuscular injection or intravenously for the short-term treatment of moderately severe pain. "ROX-888 is an important breakthrough in treating pain," said Dr. Neil Singla, Director of Clinical Research at Huntington Memorial Hospital in Los Angeles. "It is rapidly absorbed into the bloodstream, and relieves pain as fast as an intramuscular injection. There is a need for new analgesics like ROX-888 that do not have the troublesome side effects and abuse risks associated with narcotic pain relievers." The Phase 3 double-blind, placebo-controlled study included 321 patients who had undergone major abdominal surgery. Patients were randomized to receive either intranasal ketorolac (30 mg) or placebo. All study participants had access to patient-controlled morphine. "Pain is at its greatest intensity in the first 24
'"/>




Page: 1 2

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
Post Your Comments:
(Date:7/28/2015)... 2015  PD-Rx Pharmaceuticals, Inc., a publicly held ... partnered with Dobson Technologies, a fully-integrated outsourced IT ... product. PD-Rx is an Application Service ... States.  Using Dobson Technologies, IaaS solution will allow ... ensure regulatory compliance, and reduce operating expenses.  "The ...
(Date:7/28/2015)... At the 2015 ICX Association Excellence ... 15 winners in the categories of digital signage, ... vertical markets. ContextMedia:Health proudly took home the ... success with its first-to-market Patient Education Exam ... leading provider of digital solutions at point-of-care, ...
(Date:7/28/2015)... July 28, 2015 Research and Markets ... the "Global Hearing Aids Market 2015-2019" ... global hearing aids market to grow at a ... Factors such as changing demographics and ... growth. The market has witnessed immense technological advances. ...
Breaking Medicine Technology:PD-Rx Partners With Dobson Technologies 2ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2
... be tested in AMD patients, LOUISVILLE, Ky., ... company developing medicines for the treatment,of age-related macular ... candidate, POT-4, has shown early positive safety,results in ... inhibitor, which shuts,down the complement activation cascade that ...
... collaborates with Dikembe Mutombo Foundation to improve healthcare,system ... NEW YORK, Sept. 25 The Clinton Global,Initiative ... BDX ), a,leading global medical technology company, for ... enhance immune system monitoring and,healthcare worker safety at ...
Cached Medicine Technology:Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
(Date:7/29/2015)... MO (PRWEB) , ... July 29, 2015 , ... ... of a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to ... birth defects research at their website, the Zofran Birth Defects Lawsuit Center. , ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a global provider of life insurance, annuities, employee benefits and asset management, has ... inclusive sporting event taking place in Charlotte, North Carolina on October 2-4, ...
(Date:7/29/2015)... ... July 29, 2015 , ... Elizabeth ... in Sarasota to be chosen by the manufacturer to offer and perform ... injectable, non-invasive way to treat and eliminate double chin fat,” Dr. Callahan explained. ...
(Date:7/29/2015)... ... 2015 , ... Nature’s Artisan, a new holistic oral care company, has released ... was founded by Tina Yarandi, who came up with the idea for the product ... was amazed when she learned about the incredible dental benefits of xylitol, but was ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Every July, since ... with the disease only experience through movies and television. They go to summer camp. ... the right side of the heart as it pushes hard to get blood through ...
Breaking Medicine News(10 mins):Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:Discover a New Take on Oral Care with Nature’s Artisan Gourmet Mouthwashes 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 3
... can deliver organized follow-up care for depression effectively and ... Group Health patients that the Journal of General ... After five months, compared to the half of ... half who had three online care management contacts with ...
... WEDNESDAY, March 16 (HealthDay News) -- Newly proposed national ... from power plants could prevent as many as 17,000 ... to the U.S. Environmental Protection Agency. The proposed ... a court deadline, could also prevent 120,000 cases of ...
... French . , Toronto (March 16, 2011) ... received $16 million in funding. The studies, co-funded by the ... Agency (CSA), were announced today at the University of Toronto ... Jane Aubin, Scientific Director of the Canadian Institutes of Health ...
... HealthDay Reporter , TUESDAY, March 15 (HealthDay ... chatting on cell phones while crossing the street, because ... age group than for college students. In laboratory ... aged 59 to 81 and 18 undergraduates aged 18 ...
... 2011 -- Children and adolescents growing up with inflammatory bowel ... study by researchers at McMaster University and the McMaster Children,s ... Pediatrics online, shows children and youth with the most ... 25 per cent lower than other children their age, and ...
... , TUESDAY, March 15 (HealthDay News) -- The cholera ... the 400,000 cases predicted by the United Nations, new study ... cases of the potentially deadly diarrheal disease -- an estimated ... to researchers at the University of California, San Francisco and ...
Cached Medicine News:Health News:Online messaging delivers follow-up care for depression 2Health News:EPA Proposes Tougher Air Pollution Rules for Power Plants 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Crossing Street While on Cell Phone Risky for Seniors 2Health News:Youth with IBD are less fit than their peers: McMaster study 2Health News:Haiti Cholera Epidemic Could Sicken 779,000 This Year 2
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Irrigating Cystotome, Straight, 25 g. Overall length 15 mm. 5/box....
Irrigating Cystotome, formed, 25 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Medicine Products: